



COPY OF PAPERS  
ORIGINALLY FILED

Atty. Dkt: GZ 2061.00

RECEIVED

THE UNITED STATES PATENT AND TRADEMARK OFFICE

SEP 09 2002

TECH CENTER 1600/29C

Certificate of Mailing/Transmission (37 C.F.R. § 1.8(a)):

[X] Pursuant to 37 C.F.R. § 1.8, I hereby certify that this paper and all enclosures are being deposited with the United States Postal Service as first class mail on the date indicated below in an envelope addressed to the Commissioner for Patents, Washington D.C. 20231.

[ ] Pursuant to 37 C.F.R. § 1.6(d), I hereby certify that this paper and all enclosures are being sent via facsimile on the date indicated below to the attention of Examiner \_\_\_\_\_ at Facsimile No. \_\_\_\_\_ at \_\_\_\_\_ a.m./p.m.

Dated: August 27, 2002

Name of Person Certifying: Peggy Nichols  
Printed Name: Peggy Nichols

Applicant: Oxana IBRAGHIMOV-BESKROVNAYA, et al. Examiner: HADDAD, Maher H.

Filing Date: April 26, 2001

Group Art Unit: 1644

Serial No.: 09/830,506

Title: COMPOSITIONS AND METHODS FOR TREATING POLYCYSTIC KIDNEY DISEASE

Commissioner for Patents  
Washington, D.C. 20231

**RESPONSE TO REQUIREMENT FOR RESTRICTION**

Sir:

This paper is filed in response to the Requirement for Restriction Under 35 U.S.C. § 121 issued by the U.S. Patent and Trademark Office on February 27, 2002 in connection with the above-identified application. A response to the Requirement originally was due March 27, 2002. Enclosed herewith is a Petition for a five month extension of time and authorization to charge the fee due to the undersigned's deposit account. Accordingly, in view of the filing of the Petition for the Five Month Extension of Time and payment of the fee, a response is due August 27, 2002. This reply is timely filed.

The Office required restriction among the following allegedly independent and distinct groups:

Group I, claims 1-11 and 22, drawn to an isolated antibody and a hybridoma and a diagnostic kit.

Group II, claims 12-15, drawn a recombinant polypeptide of polycystin.

Group III, claims 16-18, drawn to an isolated polynucleotide encoding polycystin and a host cell.

Group IV, claims 19-21, drawn to isolated polypeptide having an apparent molecular weight in the range of about 600 to about 800 Kd.

Group V, claims 23-27, drawn to a method for inhibiting cell-cell adhesion in a suitable tissue comprising delivering to the tissue an antibody that binds to the Ig-like domains of polycystin.

Group VI, claims 23-27, drawn to a method for inhibiting cell-cell adhesion in a suitable tissue comprising delivering to the tissue an antisense polycystin DN.

Group VII, claims 23-27, drawn to a method for inhibiting cell-cell adhesion in a suitable tissue comprising delivering to the tissue a ribozymes that recognize or cleave polycystin DNA.

Group VIII, claims 23, and 28-29, drawn to a method for enhancing cell-cell adhesion in a suitable tissue comprising delivering to the tissue an antibody.

Group IX, claims 23, and 28-29, drawn to a method for enhancing cell-cell adhesion in a suitable tissue comprising delivering to the tissue a polynucleotide.

Group X, claims 23, and 28-29, drawn to a method for enhancing cell-cell adhesion in a suitable tissue comprising delivering to the tissue a polypeptide.

Applicants elect without traverse to prosecute the invention of Group VIII, claims 23 and 28 to 29.

The Commissioner is hereby authorized to charge any additional fees which may be required by this paper, or credit any overpayment to Deposit Account No. 50-1189, Billing Ref. No. 19442-7214.

Date:

Aug. 27, 2002

Respectfully submitted,

By: Antoinette F. Konski  
Antoinette F. Konski  
Registration No. 34,202

Bingham McCutchen LLP

Formerly McCutchen, Doyle, Brown & Enersen, LLP  
Three Embarcadero Center  
San Francisco, California 94111  
Telephone: (650) 849-4950  
Telefax: (650) 849-4800